Drug Search Results
More Filters [+]

DM-005

Alternative Names: DM-005, DM 005, DM005
Latest Update: 2024-07-25
Latest Update Note: Clinical Trial Update

Product Description

DM005 is a bispecific antibody-drug conjugate (ADC) designed to treat solid tumors by targeting both MET and EGFR receptors. The bispecific antibody was assembled using common light chain antibodies produced by RenLite, a fully human antibody mouse originates from Biocytogen. Its monoclonal antibody structure facilitates easy purification and drug conjugation. (Sourced from: https://en.domabio.com/pipeline/10.html)

Mechanisms of Action: C-Met Inhibitor,EGFR Inhibitor

Novel Mechanism: No

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Doma Biopharmaceutical(Suzhou)Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for DM-005

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title